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GLP-1 analogues for neuroprotection after
out-of-hospital cardiac arrest: study
protocol for a randomized controlled trial
Sebastian Wiberg1*, Christian Hassager1, Jakob Hartvig Thomsen1, Martin Frydland1, Dan Eik Høfsten1,
Thomas Engstrøm1, Lars Køber1, Henrik Schmidt2, Jacob Eifer Møller3 and Jesper Kjaergaard1
Abstract
Background: Attenuating the neurological damage occurring after out-of-hospital cardiac arrest is an ongoing
research effort. This dual-centre study investigates the neuroprotective effects of the glucagon-like-peptide-1
analogue Exenatide administered within 4 hours from the return of spontaneous circulation to comatose patients
resuscitated from out-of-hospital cardiac arrest.
Methods/design: This pilot study will randomize a total of 120 unconscious patients with sustained return of
spontaneous circulation after out-of-hospital cardiac arrest undergoing targeted temperature management in a
blinded one-to-one fashion to a 6-hour and 15-minute infusion of either Exenatide or placebo. Patients are eligible
for inclusion if resuscitated from cardiac arrest with randomization from 20 minutes to 240 minutes after return of
spontaneous circulation. The co-primary endpoint is feasibility, defined as the initiation of treatment within the
inclusion window in more than 90 % of participants, and efficacy, defined as the area under the neuron-specific
enolase curve from 0 to 72 hours after admission. Secondary endpoints include all-cause mortality at 30 days and
Cerebral Performance Category as well as a modified Rankin Score at 180 days. The study has been approved by
the Danish National Board of Health and the local Ethics Committee and is monitored by Good Clinical Practice
units. The study is currently enrolling.
Discussion: This paper presents the methods and planned statistical analyses used in the GLP-1 trial and aims to
minimize bias and data-driven reporting of results.
Trial registration: 1) Danish National Board of Health, EudraCT 2013-004311-45. Registered on 25 March 2014.
2) Videnskabsetisk komité C, Region Hovedstaden, No. 45728. Registered on 29 January 2014.
3) Clinicaltrial.gov, NCT02442791. Registered on 25 of January 2015.
Keywords: Out-of-hospital cardiac arrest, Neuroprotection, GLP-1 analogues
Background
While the mortality after out-of-hospital cardiac arrest
(OHCA) has improved over the last decade, mortality
remains as high as 90 % [1], and even after successful
resuscitation and admission to an intensive care unit
(ICU), the in-hospital mortality is 30–50 % [2, 3]. An-
oxic brain injury remains the leading cause of death in
these patients [4]. The mechanisms causing neuro-
logical damage are complex but involve both ischemia
and reperfusion injury leading to tissue degeneration
and loss of neurological function, the extent of which
depends on duration and density of the insult [5]. Tar-
geted temperature management (TTM) may attenuate
this damage in an experimental setting [6–9], and clin-
ical trials have shown promising results in improving
neurological function and survival [10, 11]. Despite this,
the optimal target temperature is debated [12], and ac-
tive neuroprotection in addition to temperature man-
agement seems intuitively beneficial. Glucagon-like
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peptide-1 (GLP-1) analogues are approved for the treat-
ment of type 2 diabetes but have recently been suggested
to ameliorate degenerative neurological disease and re-
duce inflammation after ischemic cerebral stroke [13].
The GLP-1 analogue Exenatide has been shown to reduce
infarct volume after focal brain ischemia in mice [14] and
to reduce infarct size in a model of acute myocardial in-
farction (MI) and reperfusion in swine [15]. In humans,
patients treated with Exenatide after MI have been shown
to have a larger salvage index assessed by cardiac magnetic
resonance imaging (MRI) after 3 months [16, 17]. These
findings have been confirmed by later trials [18, 19]. In
addition, Exenatide has been well tolerated in acutely ill
patients with ST-elevation myocardial infarction with no
apparent increased risk of adverse events, including
hypoglycaemia or pancreatitis, compared to placebo [17].
The present trial will investigate the neuroprotective
capabilities of the GLP-1 analogue Exenatide adminis-
tered for 6 hours and 15 minutes within 4 hours after
the return of spontaneous circulation (ROSC) in coma-
tose patients resuscitated from OHCA.
Methods/design
This pilot study is a double-blind, randomized,
placebo-controlled, clinical trial assessing the effect of
Exenatide compared with placebo on top of TTM in
adult comatose OHCA patients. Patients are enrolled at
two tertiary Danish university hospitals offering highly
specialized cardiac care for a population of approxi-
mately 3,000,000 citizens.
Trial procedure
PHASE 1 (hospital admission to start of intervention):
Unconscious patients who have been admitted to the
hospital with sustained ROSC after OHCA are eligible
for screening. The inclusion window is 220 minutes, i.e.
from 20 minutes after ROSC (defined as ‘sustained
ROSC’) until 240 minutes after ROSC. The patient’s eli-
gibility for trial inclusion is assessed according to inclu-
sion and exclusion criteria (Table 1). If all inclusion
criteria and no exclusion criteria are met, informed con-
sent is obtained, in accordance with Danish legislation,
from two independent medical doctors not involved with
the trial. Patients are then randomly allocated to active
study drug or placebo via an internet-based randomization
algorithm available on the trial website. Baseline charac-
teristics are obtained.
PHASE 2 (duration of intervention): Phase 2 starts
when the study drug/placebo administration is initiated,
most often coinciding with the initiation of TTM. Pa-
tients are sedated and mechanically ventilated. Patients
are treated for 24 hours with an automated-feedback de-
vice with temperature control to achieve a target core
temperature (bladder) of 36 °C. After 24 hours of TTM,
patients are rewarmed to a core temperature of 37 °C
with no more than 0.5 °C per hour. Phase 2 ends when
sedation is withheld.
PHASE 3 (from end of intervention period to 72 hours
after end of intervention period): Sedation is stopped or
tapered after rewarming when temperature is at least at
37 °C. Normothermia of 37 °C +/−0.5 °C is maintained
until 72 hours from cardiac arrest if the patient is still
managed in the ICU and is comatose or sedated. How-
ever, weaning from ventilation will be attempted at the
earliest possible time during this phase based on stand-
ard procedures for the discontinuation of mechanical
ventilation. Blood is drawn at 24, 48 and 72 hours and
is later analysed for the biomarkers neuron-specific
enolase (NSE) and S100B – markers of cerebral injury.
Table 1 Inclusion and exclusion criteria
Inclusion criteria
1. Age≥ 18 years
2. OHCA of presumed cardiac cause
3. Sustained ROSC, defined as ROSC when chest compressions have
not been required for 20 consecutive minutes and signs of circulation
persist
4. Unconsciousness (Glasgow coma scale (GCS) < 8) after sustained ROSC
Exclusion criteria
1. Conscious patient (GCS≥ 8)
2. Female of childbearing potential, unless a negative human
chorionic gonadotropin (HCG) test can rule out pregnancy within the
inclusion window
3. In-hospital cardiac arrest (IHCA)
4. OHCA of presumed non-cardiac cause, e.g. after trauma, dissection/
rupture of major artery or arrest caused by hypoxia (i.e. drowning or
hanging)
5. Known bleeding diathesis (medically induced coagulopathy does
not exclude patient)
6. Suspected or confirmed acute intracranial bleeding
7. Suspected or confirmed acute ischemic stroke
8. Unwitnessed asystole
9. Known limitations in therapy and do-not-resuscitate order
10. Known disease making 180-day survival unlikely
11. Known pre-arrest cerebral performance category score (CPC) of 3 or 4
12. > 4 hours (240 minutes) from ROSC to randomization
13. Systolic blood pressure < 80 mmHg in spite of fluid loading/
vasopressor and/or inotropic medication and/or mechanical
circulatory supporta
14. Temperature on admission < 30 °C
15. Known allergy to GLP-1 analogues, including Exenatide
16. Known pancreatitis
17. Known ketoacidosis
18. Uncorrected blood glucose at admission < 2.5 mmol/l
aIf systolic blood pressure is recovering during the inclusion window, the
patient can be included
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Neurological evaluation of patients who remain in a
coma is performed by blinded physicians at 72 hours or
later after the end of the intervention period.
PHASE 4 (72 hours after the end of the intervention
period to 28 days after OHCA): Neurological status ac-
cording to the Cerebral Performance Category scale
(CPC-scale) [20], and vital status are evaluated daily in
the ICU on days 1, 2, 3, 4, 5, 6 and 7 and/or at hospital
discharge, whichever comes first.
PHASE 5 (hospital discharge/day 28 to end of trial):
Vital status and neurological status are evaluated on
days 30 and 90 and then by telephone interview on day
180. The evaluation is performed by a research nurse
blinded to the intervention allocation. Vital status will
be assessed at the end of the trial using the Danish civil
registration system. See attached Additional file 2.
Inclusion
Patients with sustained ROSC after OHCA are eligible
for inclusion if fulfilling the criteria displayed in Table 1.
Study drug administration
Preparation of study drug (Exenatide/placebo): Trained
hospital nurses not taking part in the management of
the patient will prepare infusion bags with Exenatide or
placebo. At first notice of a potential candidate for inclu-
sion in the trial, a set of study drug and placebo will be
prepared. The infusions will be prepared as follows:
First, 1.5 ml is removed from 250 ml of isotonic NaCl
and 1.5 ml of 20 % human albumin is added to prevent
binding of the study drug to the infusion material. For
every potentially eligible patient, two infusion kits will
be prepared. One is a placebo kit as described, and one
has 25 μg Byetta (Lilly, Exenatide) added. The two infu-
sion kits are labelled ‘A’ or ‘B’ by random allocation in a
computer-based randomization system and brought dir-
ectly to the ICU. The random allocation will occur via
the trial website with a specific logon for personnel in-
volved in study drug preparation. The allocation ‘A’ and ‘B’
will be chosen at random by the trial website algorithm
(randomization generated into dynamic blocks), stratified
for site and will be unblinded by the end of trial.
The cardiologist responsible for the patient’s treatment
screens the patient’s eligibility and obtains informed con-
sent from legal representatives. If the patient is eligible
for inclusion and informed consent is obtained from two
independent physicians, the patient is randomized via
the trial website to receive either infusion kit ‘A’ or ‘B’,
and the other kit is discarded. The cardiologist orders
the infusion to be given. The infusion is given in a cen-
tral or peripheral intravenous line. The nurses preparing
the infusion kits remain blinded to participant allocation,
and the nurses initiating the study drug infusion (ICU
nursing staff ) remain blinded to the preparation of the
infusion kits.
The study drug infusion is initiated by the ICU nurs-
ing staff as soon as possible at a rate of 72 ml/hour
(0.12 μg Exenatide/minute) for 15 minutes (volume to
be infused is 18 ml), followed by 26 ml/hour (0.043 μg
Exenatide/minute) for an additional 6 hours (volume to
be infused: 156 ml). This concludes the pharmacological
intervention and thus a total of 17.4 μg of Exenatide is
administered. As the allocation is blinded, the same infu-
sion rates are used in the placebo arm. For safety rea-
sons, blood glucose is monitored closely during the
administration period and for the following 2 hours.
Blood glucose and corrective glucose administration is
reported. Additional management of the patients is at
the discretion of the attending physicians. Thus, all trial
participants, care providers, investigators and outcome
assessors remain blinded to the intervention until com-
pletion of the trial. If a suspected unexpected serious ad-
verse reaction (SUSAR) is found, the sponsor has the
ability to unblind the patient’s intervention allocation
through the physician responsible for the trial website,
who is otherwise detached from the trial.
Monitoring of compliance
Infusion of study drug ‘A’ or ‘B’ will be recorded along
with time of initiation of the study drug infusion. In
addition any dose reduction or interruption of administra-
tion will be recorded. Reasons for not infusing the study
drug per protocol and any dose reduction outside of ±
5 minutes from the scheduled time point are registered.
Suspected adverse events, as well as the actions taken to
correct these and their consequences, are recorded.
Concurrent medication/treatment
Computed tomography of the brain/neck/head will only
be performed as clinically indicated, not as a routine
screening after admission. Patients will be treated with
standard therapies for cardiac diseases. Coronary angiog-
raphy, percutaneous interventions and/or open-heart
surgery will be performed according to current guide-
lines at the discretion of the treating physician. Neces-
sary cardiac interventions will not be delayed by the trial
intervention; however, efforts will be made to maintain
the study drug infusion and TTM during treatment.
Logistics
The study is enrolling at two tertiary centres with ex-
perience in conducting clinical trials. All investigators
have been trained and ‘good clinical practice’ (GCP) cer-
tified. Other involved personnel (i.e. ICU nurses) have
been trained in their specific roles.
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Endpoints
The co-primary endpoints are as follows:
1. Feasibility, defined as > 90 % initiation of study drug
administration within 4 hours following ROSC in
patients eligible for inclusion
2. Efficacy, defined as the area under the NSE curve
from admission to 72 hours post-admission. Missing
data will be imputed.
Secondary endpoints are as follows:
1. Area under the S100B curve with daily measurements
until 72 hours, and absolute NSE and S100B values at
48 hours. Missing data will be imputed.
2. Composite outcome of all-cause mortality and poor
neurological function, defined as the modified Rankin
Scale (mRS) 4–6 at 30 days (telephone assessment)
3. Vital status at 7 days and at least 180 days (end of
the study) after OHCA by registry-based follow-up
4. Assessment of CPC and mRS at 90 days
5. Area under the creatine kinase MB (CK-MB) and
troponin T curve from 0 to 24 hours. Missing data
will be imputed.
6. Safety, defined as the cumulated incidence of serious
adverse events (SAE) related to the study drug:
death, need for mechanical hemodynamic support,
hypoglycaemia < 3.0 mmol/l, pancreatitis (S-
amylase > 3 UNL), need for renal replacement
therapy in the first 3 days. In addition,
hypoglycaemia and pancreatitis will be reported
separately as additional safety.
Tertiary endpoints are as follows:
1. Left ventricular ejection fraction on last in-hospital
echocardiography, stratified by the presence of acute
myocardial infarction as the cause of cardiac arrest.
Patients dying during the index administration in
whom a post-TTM echocardiography is not available
will be given the lowest LVEF score seen in each
allocation group. Missing data will be imputed.
2. Presence of EEG findings associated with poor
prognosis and EEG performed as part of per-
protocol prognostication
3. Vital status at 180 days and telephone-based CPC
and mRS at 180 days
4. Vital status at 180 days stratified for cause of death
(i.e. neurological versus cardiovascular and other –
will be adjudicated by two intensive-care consultants
blinded to treatment allocation)
Blinded efficacy variables will be recorded at 3, 30, 90
and 180 days. The telephone-based assessment will be
performed by a single trained study nurse, not otherwise
involved in the care of patients. Other variables will be
assessed and recorded in the case report forms (CRF) by
a trained physician not involved in the care of patients.
The NSE and S100B plasma levels will be measured in
the hospital laboratory for each site and recorded in the
CRF. The study drug allocation will remain blinded until
all follow-up data have been recorded. All CRFs will be
entered into the trial database. The quality of data entry
will be evaluated by random samples as well as range
checks for data values. Individual patient data will be
handled as ordinary chart records and will be kept ac-
cording to national legislation.
Data monitoring
A Data Safety Monitoring Committee (DSMC) will be
assembled. The DSMC will be responsible for safeguard-
ing the interests of trial participants, assessing the safety
and efficacy of the interventions during the trial, and for
monitoring the overall conduct of the clinical trial. The
DSMC will provide recommendations about stopping or
continuing the trial to the Steering Group (SG) of the trial.
To contribute to enhancing the integrity of the trial, the
DSMC may also formulate recommendations relating to
the selection/recruitment/retention of participants, their
management, improving adherence to protocol-specified
regimens and retention of participants, and the proce-
dures for data management and quality control.
The DSMC will be advisory to the SG. The SG will be
responsible for promptly reviewing the DSMC recom-
mendations, for deciding whether to continue or termin-
ate the trial, and for determining whether amendments
to the protocol or changes in trial conduct are required.
A statistician selected by the members of the DSMC
will perform the interim analysis. The sponsor has the
responsibility to report the overall number of SAEs and
SUSARs monthly to the DSMC. The recommendations
of the DSMC regarding stopping, continuing or chan-
ging the design of the trial should be communicated
without delay to the SG of the trial.
DSMC membership has been restricted to individuals
free of conflicts of interest. The source of these conflicts
may be financial, scientific or regulatory in nature. Any
DSMC members who develop significant conflicts of
interest during the course of the trial should resign from
the DSMC. One ‘Formal Interim Analysis’ meeting is
planned to review data relating to the treatment efficacy,
patient safety and quality of trial conduct.
The independent GCP units include data quality mon-
itoring, informed written consent forms and adjudication
of endpoints as well as results of NSE and S100B analysis.
The protocol is adapted to the ‘Standard Protocol Items:
Recommendations for Interventional Trials’ (SPIRIT), and
an additional file is added listing each paragraph and its
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location in the protocol (Additional file 1). In addition an
additional file displays the timing schedule of the enrol-
ment, interventions and assessments (Additional file 2).
Safety
The study population, which consists of resuscitated
OHCA patients admitted to the ICU, is a severely ill group
of patients. Most adverse events (AE) are common in this
patient group irrespective of treatment strategies. AEs will
be recorded daily. Adverse events relevant to the study
drug are considered to be death, the need for mechanical
hemodynamic support, hypoglycaemia < 3.0 mmol/l, pan-
creatitis (S-amylase > 3 units per liter), and the need for
renal replacement therapy in the first 3 days.
Adverse events (AE)
1. Bleeding: From nose, gastrointestinal tract, oral
cavity, genitals, insertion sites and intra-muscular
and other bleeding
2. Major bleeding: Uncontrolled bleeding (>1 unit of
blood/10 kg/hour), bleeding causing fatality,
symptomatic bleeding in a critical organ, e.g.
intracranial, intraspinal, intraocular, intraarticular or
pericardial. In addition, other bleeding, e.g.
retroperitoneal, muscular, solid organ or thoracic with
haemoglobin < 50 g/l and requiring > 2 units of blood
3. Infection: Severe sepsis, septic shock, pneumonia
or other
4. Renal impairment: Need for continuous renal
replacement therapy or intermittent haemodialysis
5. Electrolyte disorders: Sustained hyperglycaemia
(>10 mmol/l > 4 hours) or hypoglycaemia
(<3.0 mmol/l)
6. Arrhythmia: ventricular fibrillation, sustained
ventricular tachycardia, tachycardia > 130/min,
bradycardia < 40/min, atrial flutter, atrial fibrillation,
need for pacing or circulatory collapse mandating
cardiopulmonary resuscitation (CPR).
7. Seizures: Tonic-clonic, myoclonic or electrographic
status epilepticus.
8. Shivering
Safety variables and AEs will be recorded continuously
during the first 7 days and will be reported within
24 hours from awareness of the AE. AEs occurring later
than this will be evaluated at the scheduled telephone
follow-up calls at 180 days.
Serious adverse events (SAE)
For every AE reported in the CRF, an additional question
will be asked: Has there been any SAE during the last
24 hours? An SAE is an AE that results in death, is life
threatening and requires prolongation of hospitalisation
or results in significant disability/incapacity. Uncon-
trolled bleeding (>1 unit of blood/10 kg/hour), bleeding
causing fatality, intracerebral bleeding, septic shock and
life threatening arrhythmia mandating CPR will always
be considered an SAE.
Suspected unexpected serious adverse reactions (SUSAR)
A SUSAR is an unexpected and serious AE with pre-
sumed relation to the investigational drug. The term ‘un-
expected’ is defined using the Byetta® Summary of
product characteristics (http://www.ema.europa.eu/docs/
en_GB/document_library/EPAR_-_Product_Information/
human/000698/WC500051845.pdf ), current as of 19
January 2014, as the reference document. The primary
investigator as sponsor is responsible to report all ser-
ious (fatal or life threatening) SUSARs to the Danish
Health and Medicines Authority as soon as possible and
no later than 7 days after having been made aware of
such an event. For all other SUSARs, the Danish Health
and Medicines Authority must be informed as soon as
possible and no later than 15 days after the sponsor has
been made aware of the event.
All AEs, SAEs and SUSARs will be recorded and eval-
uated by the sponsor. The AEs will be reported in the
electronic AE form no later than 24 hours from aware-
ness of the AE. Each SAE and SUSAR requires that the
investigator fill in the AE form, which is included in the
CRFs. The following variables will be recorded: descrip-
tion of the event, onset and end of the event, severity,
relation to intervention, action taken and outcome. Any
AE occurring during the trial will be treated according
to established standards, and the patient will be followed
until the event has disappeared or until the condition
has stabilised.
Sample size estimation
The primary outcome is feasibility and the area under
the NSE curve (NSE AUC) at 72 hours. Since no dif-
ference in feasibility is expected and the trial is de-
signed as a pilot study, we have chosen to power this
study according to differences in the NSE AUC. A
difference of 20 % is defined as the minimal clinically
relevant difference. Previous studies have found a
value of approximately 20 μg/ml (25–75 % CI 10–45)
at 72 hours [21]. We expect a mean AUC at 72 hours
of 50 μg/ml*day, assuming an SD of 30 % of the
mean AUC. The α is set at 0.025 (co-primary end-
point), which gives a power of 90 % if 50 patients are
included in both groups. A 10 % loss of final meas-
urement is expected (patients expiring before full
72 hours). Therefore, we aim to include 120 patients
in total.
Wiberg et al. Trials  (2016) 17:304 Page 5 of 9
Statistical analysis plan
General principles
The general principles for statistical analyses will be:
1. Analyses will be performed according to the
intention-to-treat principle with patients lost to
follow-up included in the denominator [22].
2. A two-sided significance level of 0.025 will be
applied to the primary endpoints and 0.05 will be
applied to the secondary endpoints.
3. The two trial sites will be asked to complete all
CRFs and other forms if missing data is found in the
electronic database. Missing data will be reported in
the publication.
4. More than 5 % missing data in outcome variables
(see Endpoints) will result in multiple imputation
with the creation of 10 imputed datasets to be
analysed separately and then aggregated into one
estimate of the intervention’s effect on the primary
and secondary endpoints [23, 24].
Trial profile
A flowchart of the study participants will be displayed
according to the Consolidated Standards of Reporting
Trials (CONSORT) diagram [25] as Fig. 1.
Baseline data
The predefined baseline variables will be as follows:
1. Sex
2. Age
3. Comorbidities (pre-morbid CPC, NYHA class 3 or
worse, previous myocardial infarction, ischemic
heart disease, previous arrhythmia, previous cardiac
arrest, arterial hypertension, transient ischemic
attack or stroke, epilepsy, diabetes, asthma or
chronic obstructive pulmonary disease, chronic
haemodialysis or peritoneal dialysis, hepatic
cirrhosis, haematological malignancy, other
malignancy, AIDS, alcoholism, intravenous drug
abuse, or other immunodeficiency)
4. Previous percutaneous coronary intervention
5. Previous coronary artery bypass graft
6. Previous valvular surgery
7. Implantable cardioverter-defibrillator and/or
pacemaker
8. Pre-hospital variables
a. Location of cardiac arrest
b. Bystander witnessed arrest
c. Bystander CPR
d. Shockable primary rhythm
e. Time to basic life support
f. Time to advanced life support
g. Time to ROSC
9. Admission variables
a. First measured temperature
b. Glasgow Coma Score
c. Shock at admission
d. ST-elevation acute myocardial infarction
e. pH
f. Lactate
g. Creatinine
Possible differences in baseline characteristics be-
tween the treatment groups will be analysed and dis-
played in Table 1. Continuous variables will be
presented as mean ± SD, and differences will be ana-
lysed with the t test. In case of skewed data, continuous
variables will be presented as median (inter-quartile
range) and a t test will be applied following logarithmic
transformation; secondarily, a non-parametric Mann-
Whitney test will be applied. Categorical variables will
be presented as n (%) and differences will be analysed
with the chi-square test.
Analysis of endpoints
Primary outcome The primary outcome of feasibility will
be reported as the absolute percentage (with 95 % confi-
dence interval) of patients in whom the study drug admin-
istration was initiated within 240 minutes of ROSC and
the proportion in whom the study drug infusion was com-
pleted. The difference in NSE AUC between treatment
groups will be tested with the independent-sample t test
after logarithmic transformation (log2) to approximate a
normal distribution. Missing NSE values will be imputed.
Secondary and tertiary outcomes Differences between
treatment groups will be analysed with an independent
sample t test or chi-Square test depending on the vari-
able being numerical or categorical. In case of skewed
data, logarithmic transformation will be applied to ap-
proximate normal distribution. Crude survival analyses
stratified to the treatment groups are performed using
proportional hazard models. Hazard rates will also be re-
ported adjusted for site, sex, age, shock-able primary
rhythm, and time to ROSC (logarithmically trans-
formed). Hazard ratios will be presented with 95 % con-
fidence intervals.
Subgroup analyses Subgroups will be analysed accord-
ing to pre-defined design variables: over or under me-
dian age, shockable rhythm, sex, the presence of shock
at admission, diagnosed AMI and over or under median
time from arrest to ROSC. Difference in intervention
effect estimates according to subgroup will be declared
exclusively based on a statistically significant test of
interaction.
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Ethical justification
Participation in the GLP-1 trial will not interfere with or
delay routine diagnostic or therapeutic procedures. The
trial investigates a potential beneficial effect of the GLP-
1 analogue Exenatide, which seems to have effect in vari-
ous degenerative neurological conditions and has been
associated with reduced cerebral infarct size in animal
studies. The current knowledge and safety data of intra-
venous infusion in patients with acute diseases have
been referenced above.
The ethical justifications for interventions in the GLP-
1 trial are as follows:
1. Knowledge of the neuroprotective effect of GLP-1
analogues in comatose patients resuscitated after
OHCA cannot be gained outside the acute setting.
Research in a non-acute setting is not possible, and
assessment in a human experimental model is obvi-
ously unethical.
2. The interventions should be initiated as soon as
possible after ROSC to alleviate the reperfusion
injury and to reduce progressive brain injury by
apoptosis. Therefore, consent from patients is not
feasible and awaiting the consent of relatives would
induce an unacceptable institutional delay of study
drug administration in most cases.
3. The administration of the study drug is considered
safe and only exposes the patient to a minimal risk
based on previous studies in patients with ST-
elevation myocardial infarction [17].
4. Increased knowledge of the therapeutic potential of
pharmacological attenuation of anoxic brain damage
would increase the scientific knowledge of the
condition for the individual and other patients
resuscitated from OHCA.
5. Any relevant previously expressed objections to
participation in clinical trials by eligible patients
known to the researcher will be respected, including
the termination of study participation by request
from the next of kin.
6. Inclusion in the trial may be of value to the individual
patient but is valuable to the group of patients in
general because further knowledge is needed to
continue the optimisation of neuroprotective
interventions in the post-resuscitation phase.
Publication
The trial’s results will be published in international peer-
reviewed journals with no restrictions. Authorship will
be granted in accordance with the Vancouver Protocol.
The physicians involved in the trial will write the resulting
articles, and professional writers will not be used. The
study database will be maintained for 15 years. Sebastian
Wiberg and Jesper Kjaergaard will be responsible for
collecting the data for final analysis. The treatment alloca-
tion code will remain concealed until the database is
locked. GCP monitoring is performed on the endpoints as
well as on the inclusion and exclusion criteria. Analyses
and data access will be logged and restricted hereafter.
The dataset will be made publically available after 2 years
by inquiry to the principal investigator (PI).
Discussion
Due to the acute setting of this pharmaceutical trial in
combination with the serious prognoses for the patients
involved, a number of interesting challenges have arisen.
Adverse events
Primarily, our population consists of severely ill patients
with a high mortality rate. This makes adjudication of
the AEs, SAEs and SUSARs challenging. Thus, the prin-
cipal investigator or delegated investigator evaluates and
adjudicates AEs on a day-to-day basis and reports to
relevant authorities according to Danish legislation. In
the event of a suspected SUSAR, the digital algorithm
can unblind the treatment allocation of a single patient
through the trial website. If this becomes necessary, it
will be reported along with the results of the study.
Surrogate endpoints
Secondly, our primary endpoint defined as area under
the NSE-curve at 72 hours is a surrogate marker for
poor neurological outcome and death. The surrogate
marker is used instead of a hard endpoint in order to
power this pilot study adequately. Previously, NSE has
been shown to be a solid marker for poor outcome after
OHCA in patients undergoing TTM, with an area under
the receiver operating characteristics curve of 0.86 [26].
Thus, our surrogate endpoint reflects the clinically rele-
vant question of whether Exenatide has neuroprotective
effects in our population.
In conclusion, this article describes the design and
planned analysis used in the GLP-1 trial for the first publi-
cation of the primary outcomes. This approach minimizes
the overall risk of bias and data-driven results.
Trial status
The trial is currently ongoing.
Additional files
Additional file 1: SPIRIT checklist. Each SPIRIT paragraph has been
addressed regarding location in the protocol. (DOC 122 kb)
Additional file 2: SPIRIT figure. Schedule of enrolment, interventions,
and assessments. (DOC 74 kb)
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Consent for publication
At randomization, eligible patients are unconscious and unable to give informed
consent. Since the GLP-1 analogues are thought to be neuroprotective through
mechanisms reducing reperfusion injuries in the myocardium and brain [17, 27],
infusion of the study drug must be initiated as soon as possible. Thus,
randomization is justified before informed consent can be obtained according
to the Declaration of Helsinki, the Logistics Section. Preceding randomization, a
legal representative, i.e., two physicians not involved in the treatment of the
patient and one who is a clinical expert in the field, will be informed, and
consent will be obtained. As soon as possible, possibly after initiation of the
study drug, the next of kin will be informed and consent will be obtained. The
study drug infusion will be terminated by request from the next of kin. In
accordance with Danish legislation, the patient’s general practitioner will be
informed on the first coming weekday, and informed consent will be obtained.
Informed consent will be obtained from all patients regaining consciousness.
Legal representatives, next of kin, general practitioners and patients will be
provided with written and oral information on the trial in order to enable them
to make an informed decision about participation. All consent forms will be
signed by the consenter and the investigator seeking consent.
Ethics approval and consent to participate
The trial is conducted in accordance with national and international
standards for good clinical practice and is monitored by the independent
GCP unit, Bispebjerg Hospital, Copenhagen, and GCP unit of Region
Southern Denmark. In addition the study is being surveyed by a DSMC that
has full access to the study database upon request. The protocol and any
amendments including written information and the consent forms have
been formally approved prior to initiation of the trial by the local ethics
committee, ‘Videnskabsetisk komité C for Region Hovedstaden’ (reference
number 45728). In addition the study has been approved by the Danish
National Board of Health (protocol number 2013-PHARMACA-001, EudraCT
number 2013-004311-45). The full protocol is available at www.clinicaltrials.
gov (ID no. NCT02442791).
Tasks and responsibilities
The principal investigator is responsible for interacting with the sponsor; for
coordinating the protocol development, funding, ethical approval,
information, recruitment of trial sites, and daily management; and for
authorizing invoices.
The steering group is responsible for protocol development, funding,
information, recruitment of trial sites, and sub-study coordination. The
national coordinators coordinate sites at a national level and obtain ethical
approval and GCP monitoring.
The trial site investigators are responsible for all trial-related procedures at
their site, including temperature management; ensuring availability of the
study drug; training for monitoring of study drug preparation quality and
protocol adherence; educating the staff in trial-related procedures, recruitment
and follow-up of patients; and performing data entry. Clinical staff at the trial
sites will perform treatment of trial patients.
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